← Clinical Trials
Healthy Adult Subjects Phase 1 Registry Results NCT03381547

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518): Complete Statistical Analysis

This randomized, open-label, three-way crossover study evaluated pegilodecakin pharmacokinetics after different dose levels and formulations in healthy adults. The registry record does not report numerical results for the primary pharmacokinetic endpoint.

Trial start: 2017-12-18  ·  Enrollment: 12  ·  Sponsor: Eli Lilly and Company
Scope of this record

This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.

1. Trial at a Glance

This page covers the registry results for A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (NCT03381547), a randomized phase 1 study. The primary outcome is Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of Pegilodecakin.

12
Enrollment
Phase 1
n/a
Arms
In the primary outcome
n/a
Effect
No re-analysis shown
n/a
95% CI
See limitations
FeatureRegistry value
ClinicalTrials.gov identifierNCT03381547
PhasePhase 1
ConditionHealthy Adult Subjects
AllocationRandomized
Design modelCrossover
MaskingNone (open label)
Enrollment12
Arms in the primary outcomen/a
Lead sponsorEli Lilly and Company
Results postedYes

2. Clinical Question

Population

Healthy adult subjects. Enrollment was 12. The primary endpoint population was defined as randomized participants who received at least one dose of study drug and had evaluable pharmacokinetic data.

Intervention

Pegilodecakin, given as a single subcutaneous dose in each treatment period. The three treatments varied by dose and formulation concentration. For participants weighing at or below 80 kg, Treatment A was 0.8 mg at 4 mg/mL, Treatment B was 0.4 mg at 4 mg/mL, and Treatment C was 0.4 mg at 2 mg/mL. For participants weighing >80 kg, the corresponding doses were 1.6 mg, 0.8 mg, and 0.8 mg.

Comparator

The study compared the pharmacokinetic profiles associated with Treatments A, B, and C. Treatment A and Treatment B used the 4 mg/mL formulation at different dose levels; Treatment C used the 2 mg/mL formulation. The registry record describes no separate placebo or untreated comparator.

Primary question

How did maximum serum concentration, or Cmax, differ across the pegilodecakin dose levels and formulations? The registry lists Cmax as the primary pharmacokinetic outcome, with results intended to be expressed as a geometric mean and geometric coefficient of variation. Numerical Cmax estimates and a treatment comparison are not reported in the registry record.

This is a pharmacokinetic question: it concerns drug concentrations measured in serum after dosing, rather than a comparison of clinical symptoms, disease outcomes, or treatment benefit. The crossover structure means the study was designed to assess multiple treatment conditions within a study framework involving the same participant population. The record does not specify the treatment sequence or how the sequence was assigned. Nor does it report a formal statistical contrast that identifies which pair of treatments was the main comparison.

For the primary outcome, samples were scheduled at predose and at specified post-dose times across Periods 1, 2, and 3. The schedule extended through 168 hours post-dose, including a predose sample at the start of the next period. The posted results do not give the Cmax values at the treatment level, estimates of differences between treatments, confidence intervals, or significance tests. The clinical question can therefore be identified from the study design and endpoint, but the size and precision of any treatment differences cannot be assessed from the registry record.

3. Trial Design

This was a Phase 1, randomized, open-label study with a three-way crossover model. The stated aim was to evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants. Enrollment was 12. The record lists the study as completed, with a start date of 2017-12-18 and primary completion date of 2018-02-13.

Each treatment was a subcutaneous pegilodecakin dose. Treatment A used the 4 mg/mL formulation, with a 0.8 mg dose administered in 0.2 mL for participants weighing at or below 80 kg and a 1.6 mg dose administered in 0.4 mL for participants weighing >80 kg. Treatment B also used 4 mg/mL: 0.4 mg in 0.1 mL for participants at or below 80 kg and 0.8 mg in 0.2 mL for participants >80 kg. Treatment C used 2 mg/mL: 0.4 mg in 0.2 mL for participants at or below 80 kg and 0.8 mg in 0.4 mL for participants >80 kg.

In a crossover design, participants receive multiple treatment conditions in separate periods, so each person may contribute pharmacokinetic information under more than one condition. This structure can support within-participant comparisons, which may account for some differences between individuals. The registry record does not report the assigned treatment sequences, the length of any washout interval, or the rationale for choosing this design. Those details matter when interpreting whether period or carryover effects were considered.

The study was open label, meaning masking was listed as none. The record does not report whether laboratory personnel or anyone involved in the pharmacokinetic analysis was masked. The primary endpoint was maximum drug concentration in serum, summarized using a geometric mean and geometric coefficient of variation. Sampling was scheduled during each of the three periods, from predose through 168 hours post-dose. The posted results do not include numerical results for this endpoint or a reported treatment comparison. The registry record also does not report a statistical analysis plan or a justification for the enrollment target.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 3-way crossover study with 7 days washout period between doses.Two dose concentrations and two dose levels per weight bracket (participants who weighed at less than or equal to (≤) 80 kilogram (kg) (Body weight ≤ 80 kg) in the lower bracket and participants who weighed greater than (\>) 80 kg in the higher bracket (Body weight \>80 kg) were evaluated

Period 1

StageSequence ABCSequence BACSequence CBA
STARTED444
Received at Least 1 Dose of Study Drug444
COMPLETED444
NOT COMPLETED000

Period 2

StageSequence ABCSequence BACSequence CBA
STARTED444
COMPLETED444
NOT COMPLETED000

Period 3

StageSequence ABCSequence BACSequence CBA
STARTED444
COMPLETED444
NOT COMPLETED000

Analysis population for the primary outcome, as defined in the registry: All randomized participants who received at least one dose of study drug and have evaluable PK data.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All randomized participants.

CharacteristicUnitSequence ABCSequence BACSequence CBATotal
Participants analysed44412
Age, Continuousyears41.0 (SD 9.06)33.8 (SD 7.63)28.8 (SD 9.57)34.5 (SD 9.53)
Sex: Female, Male: FemaleParticipants1247
Sex: Female, Male: MaleParticipants3205
Ethnicity (NIH/OMB): Hispanic or LatinoParticipants2226
Ethnicity (NIH/OMB): Not Hispanic or LatinoParticipants2226
Ethnicity (NIH/OMB): Unknown or Not ReportedParticipants0000
Race (NIH/OMB): American Indian or Alaska NativeParticipants0000
Race (NIH/OMB): AsianParticipants0000
Race (NIH/OMB): Native Hawaiian or Other Pacific IslanderParticipants0000
Race (NIH/OMB): Black or African AmericanParticipants0101
Race (NIH/OMB): WhiteParticipants43411
Race (NIH/OMB): More than one raceParticipants0000
Race (NIH/OMB): Unknown or Not ReportedParticipants0000
Region of Enrollment: United StatesParticipants44412

6. Primary Endpoint

The registry lists the primary outcome as Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of Pegilodecakin, measured over Period 1: Days 1-4 and Day 8 [Predose, 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose (Day 8 predose)]; Period 2: Days 8-11 and Day 15 [same as Days 1-4 and Day 8 (Day 15 predose)]; Period 3: Days 15-18 and Day 22 [same as Days 1-4 and Day 8].

ElementRegistry entry
Result typeGeometric Mean
Measure of spreadGeometric Coefficient of Variation
Unitpicogram per milliliter (pg/mL)
Endpoint classificationnot reduced to a single comparison

The primary endpoint was the maximum serum concentration of pegilodecakin, called Cmax, measured in picograms per milliliter. Cmax represents the highest observed serum concentration after a dose within the specified sampling schedule. It is a pharmacokinetic measure: it describes drug concentration over time, not a clinical outcome or a measure of how a participant feels or functions.

Maximum concentration is used in pharmacokinetic studies to characterize the peak level reached after dosing. Comparing Cmax across dose levels or formulations can help describe whether the concentration profiles differ under those conditions. In general, Cmax is interpreted alongside other pharmacokinetic measures and the timing and completeness of sample collection. This general description does not establish what the observed concentrations were in this trial.

The record specifies geometric mean as the summary measure and geometric coefficient of variation as the measure of dispersion. A geometric mean is commonly used for positive concentration data that are skewed or vary multiplicatively. The geometric coefficient of variation describes relative variability on a multiplicative scale; it is not the same as an ordinary standard deviation. These are general statistical explanations of the stated summaries.

Samples were scheduled at predose and at 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose during each period, with the 168-hour sample also identified as the next period's predose sample. The primary endpoint population included randomized participants who received at least one dose and had evaluable pharmacokinetic data. Cmax estimates, variability values, and treatment contrasts are not reported in the registry record.

7. Why No Re-analysis Is Shown

Reported as posted, not recalculated. Primary outcome has several categories or time points; not reduced to one comparison. A result is recalculated only when the posted data support a clean two-arm comparison, so no result is shown beyond what the sponsor posted.

8. Statistical Interpretation

Clinical Biostats interpretation

The registry record identifies the primary pharmacokinetic question and the planned summary for Cmax, but it does not report numerical Cmax results. There is therefore no posted estimate from which to describe the peak concentration under Treatment A, Treatment B, or Treatment C, and no numerical treatment difference to interpret. The record also does not report a confidence interval, p-value, or analysis result for a treatment comparison. It cannot establish the direction, magnitude, or precision of differences among the treatment conditions.

The design was a randomized crossover study, which is intended to expose participants to multiple treatment conditions across separate periods. General statistical interpretation of a crossover study may consider within-participant comparisons, sequence, period, and possible carryover effects. The registry record does not state the treatment sequences, washout details, or analysis model, so it is not possible to determine how those design features were handled analytically. The design label alone does not show that any particular adjustment was made.

The geometric mean and geometric coefficient of variation are appropriate kinds of summaries for positive pharmacokinetic concentrations when variability is multiplicative or the distribution is skewed. That general rationale does not substitute for the actual estimates. Without the observed Cmax values and their uncertainty, readers cannot judge whether the data were tightly or widely distributed, whether the treatment profiles were similar, or whether apparent differences could be explained by sampling variability.

The record lists four outcome measures, and the primary outcome includes multiple sampling times and periods. The registry indicates that the primary outcome has several categories or time points and was not reduced to one comparison. This makes it especially important not to treat the study as if one prespecified contrast and one inferential result had been posted. The number of analyses listed is zero; no analysis results are available in the registry record.

Enrollment was 12, and the study population was healthy adults. These registry entries describe the scale and setting of the study but do not establish the precision of any estimate. Precision would depend on the observed concentrations, their variability, the completeness of evaluable data, and the statistical analysis. Those details are not reported. Likewise, no inference about clinical benefit or harm follows from a pharmacokinetic endpoint alone. The posted information supports a description of the study question and design, but not a conclusion about whether one dose or formulation produced a higher or lower Cmax.

Any sample-size calculations presented as planning illustrations should be read as assumptions-based planning, not as observed power. The stated illustration assumptions use a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a stated fraction of the observed effect. The registry record does not report a trial-specific sample-size justification or the numerical results needed to assess such illustrations as evidence about this study.

9. Statistical Methods Explained

What does the geometric mean describe?

General explanation: the geometric mean is a summary of positive values calculated on a multiplicative scale. It can be useful when values are right-skewed or when proportional changes are more meaningful than equal absolute changes. For pharmacokinetic concentrations, the geometric mean can provide a typical concentration summary without treating a given absolute increase as equally important at every concentration level. The registry lists the geometric mean for Cmax, but does not provide the resulting estimate.

The geometric coefficient of variation describes relative dispersion on a multiplicative scale. In general, it indicates how much observations vary in relation to the geometric mean. It is not interchangeable with the standard deviation, and it should be interpreted using the scale on which it is defined. The registry record names this dispersion measure but does not report its value for any treatment.

What does Cmax measure?

General explanation: Cmax is the maximum measured concentration after dosing within a defined collection schedule. Its value depends on the timing of blood sampling as well as the concentration profile. If samples are collected too sparsely to capture a peak, the measured maximum can differ from the true peak between sample times. This is a general consideration; the record specifies the sampling schedule but does not report whether any samples were missed or how missing samples were handled.

The listed schedule includes predose and multiple post-dose times during each treatment period, extending through 168 hours post-dose. The endpoint is serum concentration, with units of picograms per milliliter. The registry describes Cmax as the maximal serum concentration. It does not provide a concentration-time plot or numeric Cmax summaries in the posted results, so the observed peak profile cannot be reconstructed from the record.

Why use a crossover design?

General explanation: in a crossover study, participants receive different treatments in separate periods. Since a participant may contribute data under several conditions, an analysis can compare treatment responses within the same person. This can help separate treatment differences from stable differences between participants. It does not automatically eliminate all sources of bias or variability. Period effects, sequence effects, and carryover from an earlier treatment may matter, and the analysis needs to account for relevant design features.

The registry identifies a randomized three-way crossover model and three pegilodecakin treatments. However, the treatment order and washout interval are not reported in the registry record. The statistical model and any adjustments for period, sequence, or participant are also not reported. It is therefore not possible to say how within-participant information was used in the sponsor's analysis or whether particular crossover assumptions were assessed.

What does randomization contribute?

General explanation: random assignment can reduce systematic differences in treatment assignment when a study compares conditions. In a crossover design, randomization may apply to treatment sequence, but the registry record does not describe the sequence allocation. Randomization does not ensure identical groups or guarantee that every possible bias has been prevented, especially in a small study. The record identifies the study as randomized but gives no further details about the method used.

What can confidence intervals and tests tell readers?

General explanation: a confidence interval expresses the uncertainty around an estimated quantity under the assumptions of the statistical method. It helps readers assess which values are compatible with the data and analysis. A p-value, when reported, describes how unusual the data would be under a specified null hypothesis and statistical model. Neither measure alone indicates clinical importance, and neither can be interpreted without knowing the estimate and analysis being tested.

No confidence interval, p-value, or numerical treatment effect is reported for the primary endpoint. No analysis result is listed in the registry record. Accordingly, statistical significance and precision cannot be evaluated from the posted results. It would not be appropriate to infer either from the enrollment, the design label, or the endpoint summary method.

How should planning calculations be read?

General explanation: a sample-size calculation uses assumptions about the effect to detect, variability, allocation, and statistical method to illustrate a planning requirement. It is not a measure of the probability that a completed study found a true effect. The registry's stated planning illustration uses a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; it defines the target effect as a stated fraction of the observed effect. Such values are planning illustrations, not observed power.

The record does not give a trial-specific sample-size justification. It also does not report the numerical Cmax results needed to assess the observed effect or the variability used for a recalculation. The listed illustration assumptions should not be mistaken for the study's original design rationale or for evidence that the study had a particular ability to detect a treatment difference.

What is not established by the statistical description?

The endpoint summary method and study design do not reveal the actual outcome values. They also do not establish that a specific statistical model was used, that all planned analyses were completed, or that all randomized participants contributed evaluable data. The primary population is described as randomized participants who received at least one dose and had evaluable pharmacokinetic data, but the count meeting that definition is not reported in the registry record. Missing-data procedures and sensitivity analyses are not reported. Interpretation must therefore remain limited to the stated design, endpoint, and available safety counts.

10. Multiplicity, Missing Data and Analysis Populations

The primary endpoint is Cmax, but the registry describes several sampling times across Periods 1, 2, and 3, and states that the primary outcome has several categories or time points and was not reduced to one comparison. The record does not identify one primary treatment contrast among Treatments A, B, and C or report how multiple comparisons or repeated measurements were handled. A multiplicity adjustment, if any, is not reported in the registry record.

There are four outcome measures listed, but the posted results do not include analysis results. The number of analyses listed is zero. It is therefore not possible to determine which outcomes were analyzed, which comparisons were planned, whether analyses were adjusted, or how any exploratory analyses were distinguished from confirmatory ones. The statistical analysis plan is not reported in the registry record.

The primary endpoint population is described as all randomized participants who received at least one dose and had evaluable pharmacokinetic data. The number meeting this definition is not reported. The record does not state whether every randomized participant had evaluable data for every period or sampling time, and it does not report procedures for handling missing samples or incomplete pharmacokinetic profiles. These details can affect which participants contribute to a Cmax summary and how representative the estimates are.

General explanation: missing-data methods matter because the reasons observations are absent can affect interpretation. In pharmacokinetic studies, incomplete sampling may influence whether a maximum concentration is observed or estimable. The registry record does not describe imputation, exclusion rules beyond the stated evaluability requirement, or sensitivity analyses. These omissions mean the analysis population and the handling of incomplete records cannot be assessed in detail.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

ArmParticipants with serious adverse eventsParticipants at riskPercentage
Pegilodecakin: Treatment A0120.0%
Pegilodecakin: Treatment B0120.0%
Pegilodecakin: Treatment C0120.0%

Deaths

ArmDeaths (participants affected of at risk)
Pegilodecakin: Treatment A0 of 12
Pegilodecakin: Treatment B0 of 12
Pegilodecakin: Treatment C0 of 12

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

ArmParticipants affected of at risk
Pegilodecakin: Treatment A10 of 12
Pegilodecakin: Treatment B10 of 12
Pegilodecakin: Treatment C11 of 12

Most frequent non-serious adverse event terms

Event termOrgan systemPegilodecakin: Treatment APegilodecakin: Treatment BPegilodecakin: Treatment C
Injection site reaction right lower quadrant erythemaGeneral disorders4 of 123 of 124 of 12
Injection site reaction right upper quadrant erythemaGeneral disorders3 of 127 of 120 of 12
Injection site reaction left upper quadrant erythemaGeneral disorders1 of 120 of 127 of 12
Injection site reaction right lower quadrant pruritusGeneral disorders1 of 122 of 122 of 12
Injection site reaction left upper quadrant pruritusGeneral disorders1 of 120 of 123 of 12
Injection site reaction right upper quadrant pruritusGeneral disorders0 of 122 of 121 of 12
NauseaGastrointestinal disorders1 of 120 of 121 of 12
ChillsGeneral disorders1 of 121 of 120 of 12
Injection site reaction right lower quadrant swellingGeneral disorders0 of 121 of 121 of 12
MyalgiaMusculoskeletal and connective tissue disorders1 of 120 of 121 of 12
Do not overextend the safety comparison. Serious-adverse-event counts are safety observations, not efficacy outcomes, and should not be combined with the primary result into a single benefit-risk number.

The registry reports serious adverse events separately from other adverse events for each treatment. For Treatment A, 0 serious adverse events affected participants among 12 at risk; other adverse events affected 10 among 12 at risk. For Treatment B, the serious adverse event count was 0 among 12 at risk, and other adverse events affected 10 among 12 at risk. For Treatment C, the serious adverse event count was 0 among 12 at risk, and other adverse events affected 11 among 12 at risk. Deaths were 0 for each treatment.

These are treatment-period figures in a crossover study, not separate parallel-group samples. A participant may contribute safety information under more than one treatment condition, so the counts across treatments should not be added to infer the number of people in the study or a combined total. The registry lists no top serious adverse event terms. It does not provide further detail about the nature, severity, duration, or relatedness of the other adverse events.

The absence of reported serious adverse events in these treatment groups is a description of the posted counts, not proof that serious events cannot occur. The other adverse event counts indicate that such events were recorded, but the registry information does not establish cause or provide a comparison adjusted for the crossover structure. Safety interpretation is limited to these recorded figures and the detail available in the registry record.

12. What the Result Does, and Does Not, Mean

This study addresses a focused pharmacokinetic question: how maximum serum concentration varied across three pegilodecakin dose and formulation conditions in healthy adults. The randomized, open-label, three-way crossover design and the Cmax endpoint are reported. The registry also specifies a geometric mean summary and geometric coefficient of variation for the primary endpoint.

The key result needed to answer the stated question is not reported in the registry record. No treatment-specific Cmax estimates, variability estimates, contrasts, confidence intervals, or p-values are posted. Consequently, the available record does not show whether one treatment produced a higher or lower maximum concentration than another, how large any difference was, or how precise an estimate might be. The endpoint and design do not substitute for those results.

The record also does not support conclusions about clinical efficacy. Cmax is a measure of drug concentration, not a patient-centered outcome. Nor does the limited safety summary establish a complete safety profile: it reports serious and other adverse event counts, but not detailed event descriptions, causal assessments, or a broader assessment of harms.

The study population was healthy adult subjects and enrollment was 12. These characteristics describe the setting and scale of the trial; they do not justify extending its findings to other populations. The registry record does not report demographic details or numerical pharmacokinetic results that would allow assessment of how individual characteristics related to concentration.

Accordingly, the registry record documents the question, treatments, sampling schedule, and selected safety counts, while leaving the primary numerical result and its uncertainty unavailable. Any statement about relative exposure, statistical significance, or clinical importance would go beyond what the posted results establish.

13. Why This Trial Matters Statistically

This trial illustrates a statistical feature of pharmacokinetic research: the outcome is a measured concentration over time, and the timing of collection is part of how the endpoint is defined. Cmax is not simply a treatment label or a clinical response. Its interpretation depends on the sampling schedule and on whether a concentration maximum can be estimated from the available measurements. The registry specifies a detailed sampling schedule, making the intended measurement clear.

The three-way crossover structure is also statistically relevant. In general, crossover studies can use measurements from the same participant under multiple conditions, which may make within-participant comparisons informative. At the same time, treatment order, period effects, and possible carryover require attention. The registry record does not describe the assigned sequences, washout, or analysis model, so the design raises important interpretive questions that cannot be resolved from the posted information.

The use of a geometric mean and geometric coefficient of variation signals a multiplicative approach to summarizing concentration data. General statistical practice often uses such summaries for positive, skewed measurements. Readers need both the estimated values and their uncertainty to understand the observed pattern. Those numerical results are not reported in the registry record, so the methodological choices cannot be connected to an observed treatment comparison.

The record also demonstrates why a clearly named primary endpoint is not enough to reconstruct an analysis. Multiple periods and sampling times are listed, but no single comparison or analysis result is reported. The number of analyses listed is zero. Without a reported analysis plan and results, multiplicity handling, missing-data decisions, and model assumptions remain unclear. These features matter to biostatisticians and clinical researchers because they determine how the design is translated into an estimate and how much confidence to place in it.

14. Limitations

The main limitation for interpreting this trial is that numerical results for the primary Cmax endpoint are not reported in the registry record. There are no treatment-specific estimates, measures of variability, treatment contrasts, confidence intervals, or p-values. The central pharmacokinetic comparison therefore cannot be quantified or judged for precision from the posted results.

Although the study is identified as randomized and crossover, the registry does not report treatment sequences, washout details, or the statistical model. It does not state how period or sequence effects were assessed or how within-participant measurements were used. These omissions prevent detailed assessment of whether the analysis reflected the crossover structure.

The record identifies multiple endpoint time points and four outcome measures, but does not report a multiplicity strategy or a statistical analysis plan. Missing-data rules, the number of participants with evaluable pharmacokinetic data, and any sensitivity analyses are also not reported in the registry record. The posted information does not establish how incomplete sampling affected the endpoint summaries.

Enrollment was 12 and the participants were healthy adults. The record does not provide demographic details or a trial-specific sample-size justification. The study was open label, with masking listed as none; whether laboratory or analysis personnel were masked is not reported. Finally, the endpoint is pharmacokinetic, and the record does not provide clinical outcome results. These limits constrain both the statistical interpretation and the scope of conclusions that can be drawn.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

Continue through the Clinical Biostats statistical pathway

Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.

18. Record Summary

NCT03381547 is a completed Phase 1, randomized, open-label, three-way crossover study sponsored by Eli Lilly and Company. Its official title describes a single-dose evaluation of different pegilodecakin dose levels and formulations in healthy adult subjects. Enrollment was 12. The study started on 2017-12-18, and primary completion was 2018-02-13.

The primary endpoint was maximum serum concentration of pegilodecakin, expressed in picograms per milliliter and summarized using a geometric mean and geometric coefficient of variation. Three subcutaneous treatment conditions differed in dose and formulation concentration. The registry record reports serious and other adverse event counts by treatment, including 0 serious adverse events and 0 deaths in each treatment group.

Numerical primary endpoint results, treatment comparisons, and inferential analyses are not reported in the registry record. The record does not report the statistical analysis plan, missing-data procedures, or multiplicity handling.

Need an analysis like this for your own study?

Our team supports biostatistics, statistical programming and pharmacometric analyses. Send us a request and we will reply by email.

Request an analysis
Clinical Biostats